139 related articles for article (PubMed ID: 6242022)
1. Experience with an LHRH analogue in the management of relapsed progressive prostatic cancer.
Kerle D; Williams G; Ware H; Doble A; Allen J; Bloom SR
Br J Urol; 1984 Oct; 56(5):495-8. PubMed ID: 6242022
[TBL] [Abstract][Full Text] [Related]
2. The treatment of metastatic prostatic cancer with the slow release LH-RH analogue Zoladex ICI 118630.
Beacock CJ; Buck AC; Zwinck R; Peeling WB; Rees RW; Turkes A; Walker K; Griffiths K
Br J Urol; 1987 May; 59(5):436-42. PubMed ID: 2954605
[TBL] [Abstract][Full Text] [Related]
3. Long term therapy with a depot LHRH analogue (Zoladex) in patients with advanced prostatic cancer.
Denis L; Keuppens F; Mahler C; Debruyne FM; Weil EH; Lunglmayr G; Newling D; Robinson MR; Richards B; Smith PH
Prog Clin Biol Res; 1987; 243A():221-7. PubMed ID: 2958852
[No Abstract] [Full Text] [Related]
4. Androgen level variations, clinical response to LHRH agonists and changes in the quality of life subscales in metastatic prostate cancer--speculations about possible role of the monoamine system.
Popov I; Jelić S; Radosavljević D; Nikolić-Tomasević Z
Neoplasma; 1997; 44(5):308-13. PubMed ID: 9473791
[TBL] [Abstract][Full Text] [Related]
5. Treatment of advanced prostatic carcinoma with a slow release depot LHRH analogue (Zoladex depot).
Lukkarinen O; Kontturi M
Scand J Urol Nephrol Suppl; 1988; 110():109-12. PubMed ID: 2973121
[TBL] [Abstract][Full Text] [Related]
6. Re: Comparison of LHRH analogue (Zoladex) with orchiectomy in patients with metastatic prostatic carcinoma. A. V. Kaisary et al. Br. J. Urol., 67, 502-508, 1991.
Bunce C
Br J Urol; 1992 Apr; 69(4):441-2. PubMed ID: 1533812
[No Abstract] [Full Text] [Related]
7. A long term follow-up of patients with advanced prostatic cancer treated with buserelin.
Waxman JH; Hendry WF; Whitfield HN; Oliver RT
Prog Clin Biol Res; 1985; 185A():271-7. PubMed ID: 3929266
[TBL] [Abstract][Full Text] [Related]
8. Osteoblastic flare assessed by serum alkaline phosphatase activity is an index of short duration of response in prostate cancer patients with bone metastases submitted to systemic therapy.Gruppo Onco Urologico Piemontese (G.O.U.P).
Berruti A; Cerutti S; Fasolis G; Sperone P; Tarabuzzi R; Bertetto O; Pagani G; Zolfanelli R; Pallotti S; Bumma C; Fontana D; Rosseti SR; Dogliotti L; Angeli A
Anticancer Res; 1997; 17(6D):4697-702. PubMed ID: 9494591
[TBL] [Abstract][Full Text] [Related]
9. LHRH-analogues therapy for metastatic prostate cancer.
Debruyne FM; Fernandez del Moral P; Geboers AD
Prog Clin Biol Res; 1988; 260():27-39. PubMed ID: 2966406
[No Abstract] [Full Text] [Related]
10. [New approach in the treatment of prostatic cancer: combined use of a LHRH agonist and an androgen antagonist].
Labrie F; Dupont A; Belanger A; Lefebvre FA; Raynaud JP
J Pharmacol; 1983; 14 Suppl 3():117-35. PubMed ID: 6423907
[TBL] [Abstract][Full Text] [Related]
11. [Clinical efficacy of long-term treatment with LH-RH analogue, ICI 118630 (Zoladex), in prostatic cancer patients. The Zoladex Multicenter Study Group].
Usami M; Kotake T; Matsuda M; Okajima E; Osafune M; Akaza H; Nihsijima T; Aso Y; Araki T; Itatani H
Hinyokika Kiyo; 1988 Nov; 34(11):2059-66. PubMed ID: 2977261
[TBL] [Abstract][Full Text] [Related]
12. [Endocrine therapy for prostatic carcinoma--the clinical trial to compare the efficacy of LH-RH analogue, ICI 118630 (Zoladex) with castration or estrogen].
Usami M; Kotake T; Matsuda M; Okajima E; Osafune M; Akaza H; Niijima T; Aso Y; Araki T; Itatani H
Hinyokika Kiyo; 1988 Oct; 34(10):1853-63. PubMed ID: 2977527
[TBL] [Abstract][Full Text] [Related]
13. Treatment of advanced prostatic cancer with LHRH-analogues. Prevention of "flare-up" phenomenon.
Bouffioux C; Denis L; Mahler C; de Leval J
Prog Clin Biol Res; 1987; 243A():255-60. PubMed ID: 2958857
[No Abstract] [Full Text] [Related]
14. An LH-RH analogue (Zoladex) in the management of carcinoma of the prostate: a preliminary report comparing daily subcutaneous injections with monthly depot injections.
Robinson MR; Denis L; Mahler C; Walker K; Stitch R; Lunglmayr G
Eur J Surg Oncol; 1985 Jun; 11(2):159-65. PubMed ID: 3159598
[TBL] [Abstract][Full Text] [Related]
15. Hormonal treatment of unresectable pancreatic cancer with LHRH analogue (goserelin).
Sperti C; Pasquali C; Catalini S; Cappellazzo F; Bonadimani B; Militello C; Pedrazzoli S
Eur J Surg Oncol; 1992 Jun; 18(3):267-71. PubMed ID: 1535051
[TBL] [Abstract][Full Text] [Related]
16. A comparison between surgical orchidectomy and the LHRH agonist 'Zoladex' (ICI 188630) in the treatment of metastatic cancer of the prostate.
Peeling WB
Prog Clin Biol Res; 1989; 303():41-5. PubMed ID: 2528738
[No Abstract] [Full Text] [Related]
17. Value of biochemical markers in the management of disseminated prostatic cancer.
Mulders PF; Fernandez del Moral P; Theeuwes AG; Oosterhof GO; van Berkel HT; Debruyne FM
Eur Urol; 1992; 21(1):2-5. PubMed ID: 1376692
[TBL] [Abstract][Full Text] [Related]
18. [LHRH analogs--new possibilities in the treatment of prostatic cancer].
Baranowska B
Pol Tyg Lek; 1984 Jul 16-23; 39(29-30):1009-12. PubMed ID: 6239145
[No Abstract] [Full Text] [Related]
19. New hormonal therapy in prostatic carcinoma: combined treatment with an LHRH agonist and an antiandrogen.
Labrie F; Dupont A; Belanger A; Cusan L; Lacourciere Y; Monfette G; Laberge JG; Emond JP; Fazekas AT; Raynaud JP; Husson JM
Clin Invest Med; 1982; 5(4):267-75. PubMed ID: 6819101
[TBL] [Abstract][Full Text] [Related]
20. The effect of previous endocrine therapy on responses to a single dose of an LHRH analogue.
Allen JM; Williams G; O'Shea JP; Smith C; Yeo T; Kerle D; Bloom SR
Urol Res; 1984; 12(5):249-51. PubMed ID: 6240150
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
